University of Pennsylvania Center for Studies of Addiction, Philadelphia, PA
Medical management - Behavioral
You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.
What conditions do you have?
What conditions do you have?
This trial is testing whether the anti-inflammatory drug ibudilast can help people with alcohol dependence reduce or stop drinking. The trial will last 6 weeks, and participants will be randomly assigned to receive either ibudilast or a placebo. Ibudilast is not approved by the FDA for use in the United States, but it has been used safely and effectively for many years in Asia.
Ibudilast is a medication used to treat alcoholism.
Primary Treatment: Ibudilast · Has Placebo Group · Phase 2
Inactive placeboPlaceboComparator Group · 2 Interventions: Medical management, Placebo · Intervention Types: Behavioral, Drug
IbudilastActiveComparator Group · 2 Interventions: Medical management, Ibudilast · Intervention Types: Behavioral, Drug
Screening: ~3 weeks
Reporting: 6-week treatment period.
Closest Location: University of Pennsylvania Center for Studies of Addiction · Philadelphia, PA
2017First Recorded Clinical Trial
4 TrialsResearching Alcoholism
3 CompletedClinical Trials
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
1,797 Previous Clinical Trials
36,108,012 Total Patients Enrolled
23 Trials studying Alcoholism
3,426 Patients Enrolled for Alcoholism
Henry R Kranzler, MDPrincipal InvestigatorUniversity of Pennsylvania
3 Previous Clinical Trials
354 Total Patients Enrolled
2 Trials studying Alcoholism
353 Patients Enrolled for Alcoholism
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a stated goal to reduce drinking to safe levels or to stop drinking.
You are able to read English at an 6th grade or higher level and have no gross cognitive impairment.
You are willing to allow an individual who will know the subject's whereabouts to facilitate follow up during the study.
You are a woman of child-bearing potential (i.e., who has not had a hysterectomy, bilateral oophorectomy, tubal ligation or less than two years postmenopausal) who is not practicing a reliable method of birth control and has not had a hysterectomy, bilateral oophorectomy, tubal ligation, or less than two years postmenopausal.
You are willing to provide informed consent and to complete the study procedures.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.